Abstract: Provided is an isolated antigen binding protein capable of binding to a PD-L1 protein, capable of blocking binding between a PD-1 protein and the PD-L1 protein, and/or capable of stimulating immune cells to secrete cytokines. Also provided is use of the isolated antigen binding protein in the preparation of a drug.

Abstract: A production method for a bispecific antibody, comprising constructing cells for producing a bispecific antibody, screening the cells, culturing the cells obtained in step one to obtain a culture solution, and performing separation and purification to obtain the bispecific antibody. The cells comprise CHO cells. The culture mode comprises fed-batch culture or perfusion culture. Various influence factors in fermentation culture and separation and purification are comprehensively analyzed, and by effective control, all factors can effectively cooperate, so that a high-purity bispecific antibody is efficiently produced, the daily output can reach 3 g/L or above, and the purity of the purified bispecific antibody can reach 90% or above. Moreover, the production process is amplified and verified, the process is stable and reliable, the cost is low, a great breakthrough is achieved compared with an existing production method.

Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPBG-CH2-N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO:1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.

Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO: 1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.

Abstract: Provided is an isolated antigen binding protein capable of binding to VEGF protein and/or capable of blocking binding of VEGF protein to VEGFR protein. Further provided is a use of the isolated antigen binding protein in the preparation of a drug.

Abstract: Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors.

Abstract: An anti-MASP-2 antibody and use thereof. The anti-MASP-2 antibody specifically binds to a human MASP-2 protein at a KD value of about 2E-09M or less, and the anti-MASP-2 antibody specifically binds to a cynomolgus monkey MASP-2 protein at a KD value of about 2E-09M or less. Disclosed are an immunoconjugate containing the anti-MASP-2 antibody, a method for preparing the anti-MASP-2 antibody, and use of the anti-MASP-2 antibody.

Abstract: The present invention provides a preparation of a Siglec-15 binding protein and the use thereof, and specifically relates to an isolated antigen-binding protein, which comprises HCDR3. Provided is the use of the antigen-binding protein in the prevention and treatment of diseases.

Abstract: Provided is an GARP protein antibody, and a cell comprising or expressing the GA RP protein antibody. The GARP protein antibody binds to human GARP/human TGF-?1 complex with a KD value of about 1.0E-12 or less. Also provided are a pharmaceutical combination comprising the GARP protein antibody and an immune checkpoint inhibitor and use thereof.

Abstract: The present application relates to an antigen-binding protein comprising amino acid mutations compared with the light and heavy chain variable region sequences of omalizumab. The antigen-binding protein of the present application is an anti-IgE engineered antibody. The present application also relates to pharmaceutical compositions comprising the antigen-binding protein, and methods thereof for alleviation or treatment of diseases associated with abnormal level of IgE.

Abstract: The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)n-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3)n, or (HM-3)n-Linker-Fc(IgG)-Linker-(HM-3)n. The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

Abstract: Provided are a murine or fully human monoclonal antibody targeting SEMA4D and a preparation method therefor, wherein the antibody binds to the SEMA4D antigen and has activities such as combating tumors.

Abstract: A BLyS antibody, preparation method therefor and application thereof, the BLyS antibody comprising one or more of CDR1, CDR2 and CDR3 of a heavy chain variable region of the BLyS antibody, and/or one or more of CDR1, CDR2 and CDR3 of a light chain variable region of the BLyS antibody. An amino acid sequence of the antibody is shown in a sequence listing. The BLyS antibody has a high affinity, and may observably and effectively seal a BLyS protein at a protein level and a cell level, and prevent the BLyS protein from binding to a receptor. The BLyS antibody lacks a cross-reaction with homologous protein antigens such as human APRIL, and enjoys good biological activity. The BLyS antibody may inhibit the proliferation of human BLyS-induced mouse B cells and may therefore be used for preparing a drug for preventing or treating diseases associated with BLyS expression or dysfunction.

Abstract: The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)n-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3)n, or (HM-3)n-Linker-Fc(IgG)-Linker-(HM-3)n. The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

Abstract: The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH2—N?H-mFGF21, wherein mFGF21 consists of SEQ ID NO:1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.